Affiliations 

  • 1 Department of Oncology, University of Oxford, Oxford, United Kingdom; Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia
  • 2 Department of Oncology, University of Oxford, Oxford, United Kingdom
  • 3 Nuffield Department of Clinical Laboratory Science, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
  • 4 Department of Oncology, University of Oxford, Oxford, United Kingdom; PsiOxus Therapeutics, Abingdon, United Kingdom
  • 5 Department of Oncology, University of Oxford, Oxford, United Kingdom. Electronic address: len.seymour@oncology.ox.ac.uk
Virology, 2017 05;505:162-171.
PMID: 28260622 DOI: 10.1016/j.virol.2017.02.011

Abstract

Enadenotucirev (EnAd) is a group B oncolytic adenovirus developed for systemic delivery and currently undergoing clinical evaluation for advanced cancer therapy. For differentiated carcinomas, systemic delivery would likely expose virus particles to the basolateral surface of cancer cells rather than the apical surface encountered during natural infection. Here, we compare the ability of EnAd and adenovirus type-5 (Ad5) to infect polarised colorectal carcinoma cells from the apical or basolateral surfaces. Whereas Ad5 infection was more efficient via the apical than basolateral surface, EnAd readily infected cells from either surface. Progeny particles from EnAd were released preferentially via the apical surface for all cell lines and routes of infection. These data further support the utility of group B adenoviruses for systemic delivery and suggest that progeny virus are more likely to be released into the tumour rather than back through the basolateral surface into the blood stream.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.